Clinical Trial: Impact of Angiotensin II Receptor Blockers (ARBs) on Survival Outcomes in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Real-World Retrospective Cohort Study (China)

Posted On: 2026-09-09

China, Sept. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Impact of Angiotensin II Receptor Blockers (ARBs) on Survival Outcomes in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Real-World Retrospective Cohort Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131939

Registration Time: 2026/09/08

Type: Observational study

Primary Sponsor: Wuxi people’s Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=335377

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Impact of Angiotensin II Receptor Blockers (ARBs) on Survival Outcomes in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Real-World Retrospective Cohort Study (China)